Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers.

[1]  D. Lambrechts,et al.  Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer , 2014, Journal of the National Cancer Institute.

[2]  D. Levine,et al.  Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma. , 2014, Gynecologic oncology.

[3]  M. Köbel,et al.  POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. , 2014, Gynecologic oncology.

[4]  J. Debus,et al.  Survival of women with clear cell and papillary serous endometrial cancer after adjuvant radiotherapy , 2014, Radiation oncology.

[5]  B. Weigelt,et al.  Classification of endometrial carcinoma: more than two types. , 2014, The Lancet. Oncology.

[6]  P. Gehrig,et al.  High-grade endometrial cancer: revisiting the impact of tumor size and location on outcomes. , 2014, Gynecologic oncology.

[7]  A. Tinker,et al.  Population-based treatment and outcomes of Stage I uterine serous carcinoma. , 2014, Gynecologic oncology.

[8]  S. Leung,et al.  Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas , 2013, The American journal of surgical pathology.

[9]  M. Köbel,et al.  Reproducibility of histological cell type in high-grade endometrial carcinoma , 2013, Modern Pathology.

[10]  Tina A. Ayeni,et al.  Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. , 2013, Gynecologic oncology.

[11]  Jeong-Won Lee,et al.  A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometrioid corpus cancers using 2009 FIGO staging system , 2013, Journal of gynecologic oncology.

[12]  F. Parazzini,et al.  Clear cell and papillary serous endometrial carcinomas: survival in a series of 128 cases , 2013, Archives of Gynecology and Obstetrics.

[13]  M. Birrer,et al.  Uterine papillary serous cancer: a review of the literature. , 2012, Gynecologic oncology.

[14]  G. Schaller,et al.  Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. , 2012, Gynecologic oncology.

[15]  D. Giannarelli,et al.  Uterine Papillary Serous, Clear Cell, and Poorly Differentiated Endometrioid Carcinomas: A Comparative Study , 2011, International Journal of Gynecologic Cancer.

[16]  P. Neven,et al.  The Role of Adjuvant Chemotherapy in Surgical Stages I-II Serous and Clear Cell Carcinomas and Carcinosarcoma of the Endometrium: A Collaborative Study , 2010, International Journal of Gynecologic Cancer.

[17]  P. Gehrig,et al.  Uterine papillary serous carcinoma: epidemiology, pathogenesis and management , 2010, Current opinion in obstetrics & gynecology.

[18]  P. Gehrig,et al.  Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. , 2009, Gynecologic oncology.

[19]  P. Gehrig,et al.  Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[20]  M. Carey,et al.  Is adjuvant therapy necessary for Stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging? , 2007, International Journal of Gynecologic Cancer.

[21]  G. Fleming,et al.  The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. , 2007, Gynecologic oncology.

[22]  E. Oliva,et al.  Clinicopathologic Analysis of 187 High-grade Endometrial Carcinomas of Different Histologic Subtypes: Similar Outcomes Belie Distinctive Biologic Differences , 2007, The American journal of surgical pathology.

[23]  E. Weiderpass,et al.  Body size in relation to cancer of the uterine corpus in 1 million Norwegian women , 2007, International journal of cancer.

[24]  M. Hendrickson,et al.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers , 2006, British Journal of Cancer.

[25]  P. Neven,et al.  Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. , 2005, Gynecologic oncology.

[26]  P. Boyle,et al.  Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. , 2004, Gynecologic oncology.

[27]  V. Bae-Jump,et al.  Uterine serous and grade 3 endometrioid carcinomas , 2004, Cancer.

[28]  A. Mundt,et al.  Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. , 2003, International journal of radiation oncology, biology, physics.

[29]  Brady J. McKee,et al.  Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? , 2002, International journal of radiation oncology, biology, physics.

[30]  I. Bukovsky,et al.  Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study. , 2002, European journal of gynaecological oncology.

[31]  D. Guo,et al.  Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994. , 2000, Gynecologic oncology.

[32]  R. Bentley,et al.  The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. , 2000, Gynecologic oncology.

[33]  J. V. Bokhman.  Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.

[34]  R. Kempson,et al.  Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma , 1982, The American journal of surgical pathology.